Vertex Pharmaceuticals Incorporated VRTX announced updates on its two novel investigational candidates, zimislecel (formerly ...

Vertex halts VX-264 trials after missing efficacy goals but continues advancing zimislecel, a potential treatment for severe ...

Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to ...

research-stage immunoprotective approaches - BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several updates on the Company’s type 1 diabetes (T1D ...

Despite a $400 million impairment charge, analysts say the removal of a drug-device combo from its portfolio is not a huge ...

Vertex Pharmaceuticals saw a notable 20.53% share price increase over the last quarter, which coincided with several key developments in its Type 1 Diabetes (T1D) initiatives. The company ...

Vertex Pharmaceuticals will not advance clinical trials of a treatment for Type 1 diabetes after efficacy data failed to support further clinical advancement.

Vertex Pharmaceuticals is diversifying from its cystic fibrosis dominance into pain and other markets. Check out our ...

Vertex Pharmaceuticals Incorporated VRTX announced ... which are being developed in separate studies for the treatment of type 1 diabetes (T1D). Zimislecel is designed for the transplantation ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several updates on the Company’s type 1 diabetes (T1D) ...

Vertex Pharmaceuticals (NasdaqGS:VRTX) saw a notable 20.53% share price increase over the last quarter, which coincided with several key developments in its Type 1 Diabetes (T1D) initiatives. The ...